New heart ablation tool tested in humans for first time

NCT ID NCT07503769

ENROLLING_BY_INVITATION Disease control Sponsor: Shanghai MicroPort EP MedTech Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early study tests a new catheter that uses two types of energy (radiofrequency and pulsed field) to treat rapid heartbeats from the lower chambers. Ten adults with drug-resistant ventricular arrhythmias will receive the procedure. The main goal is to check safety and see if the abnormal rhythm stops right after treatment and at 3 months.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: dual-energy ablation catheter (radiofrequency and pulsed field)
What this could lead to: If successful, this could lead to a safer, more effective way to treat abnormal heart rhythms without long-term medication.
What could go wrong: This is a very early, small trial (10 people) focused on safety, not proof of effectiveness. The procedure carries risks like bleeding, heart damage, or arrhythmia recurrence.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PREMATURE VENTRICULAR CONTRACTIONS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Ventricular Premature Complexes ventricular tachycardia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PREMATURE VENTRICULAR CONTRACTIONS VENTRICULAR TACHYCARDIA

Contacts and locations

Locations

The First Affiliated Hospital of Ningbo University

Ningbo, Zhejiang, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.